Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans
| العنوان: | Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans |
|---|---|
| المؤلفون: | Sue Zhou, Tracey Boyden, Michael J. Potchoiba, Theresa Cosker, Deepak Dalvie, Clinton M. Schroeder |
| المصدر: | Drug Metabolism and Disposition. 36:1869-1883 |
| بيانات النشر: | American Society for Pharmacology & Experimental Therapeutics (ASPET), 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Metabolite, Glucuronidation, Pharmaceutical Science, Matrix Metalloproteinase Inhibitors, Biology, Hydroxamic Acids, Rats, Sprague-Dawley, Excretion, chemistry.chemical_compound, Dogs, Pharmacokinetics, Oral administration, Internal medicine, Matrix Metalloproteinase 13, Blood plasma, medicine, Animals, Humans, Protease Inhibitors, Tissue Distribution, Carbon Radioisotopes, Chromatography, High Pressure Liquid, Pharmacology, Sulfonamides, Blood Proteins, Metabolism, Rats, Endocrinology, chemistry, Area Under Curve, Microsomes, Liver, Female, Glucuronide |
| الوصف: | The metabolism and disposition of 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), a selective inhibitor of matrix metalloproteinase-13, was investigated in rats and dogs following oral administration of [(14)C]CP-544439. Both species showed quantitative recovery of the radiolabel, and feces was the major route of excretion. Whole-body autoradioluminography study in rats suggested distribution of CP-544439 in all tissues except central nervous system. The radiolabel was rapidly eliminated from most tissues except the periodontal ligament. Metabolism of CP-544439 was extensive in both species. Only 8.4 and 1.5% of the total dose constituted unchanged CP-544439 in the rat and dog, respectively. Similarly, pharmacokinetic analysis of [(14)C]CP-544439 and unchanged CP-544439 indicated that the exposure of the parent drug was 16 and 6.5% of the total radioequivalents in rat and dog, respectively. Metabolic profiling revealed that CP-544439 was primarily metabolized via glucuronidation, reduction, and hydrolysis. Glucuronidation was the primary route of metabolism in dogs, whereas reduction of the hydroxamate moiety was the major pathway in rats. Human plasma and urine obtained from a dose escalation study in healthy human volunteers were also analyzed in this study to assess the metabolism of CP-544439 in humans and ensure that selected animal species were exposed to all major metabolites formed in humans. Analysis suggested that CP-544439 was metabolized via all three pathways in humans consistent with rat and dog; however, the glucuronide conjugate M1 was the major circulating and excretory metabolite in humans. Preliminary in vitro phenotyping studies indicated that glucuronide formation is primarily catalyzed by UGT1A1, 1A3, and 1A9. |
| تدمد: | 1521-009X 0090-9556 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda87bf7c630e45fe60b5508db9eef96 https://doi.org/10.1124/dmd.108.022566 |
| رقم الأكسشن: | edsair.doi.dedup.....eda87bf7c630e45fe60b5508db9eef96 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1521009X 00909556 |
|---|